

EQA round: IFT1/24 - Immunophenotypisation

Deadline: 22.4.2024

Setup: groups - R (manufacturer of kit)

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

| Test Sample Group | Frequency of the results | | | | | Success | | |
|-------------------------|--------------------------|------------------|-------------------------|----------------------------------|------------------|------------------|-------------------------|--|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] | |
| (259) HLA-B27 | | 64 | | | 64 | 63 | 98 | |
| Sample A | | 64 | | | 64 | 64 | 100 | |
| (12) Beckman Coulter | CVP >>> | 43 | 67 | Negative | | | | |
| (36) Immunotech | CVP >>> | 2 | 3,1 | Negative | | | | |
| (88) Becton Dickinson | CVP >>> | 13 | 20 | Negative | | | | |
| (177) Mindray | CVP >>> | 6 | 9,4 | Negative | | | | |
| Sample B | | 64 | | | 64 | 63 | 98 | |
| (12) Beckman Coulter | CVP >>> | 43 | 67 | Positive | | | | |
| (36) Immunotech | CVP >>> | 2 | 3,1 | Positive | | | | |
| (88) Becton Dickinson | CVP >>> | 13 | 20 | Positive | | | | |
| (177) Mindray | | 1 | 1,6 | Not specified | | | | |
| | > | 1 | 1,6 | Inconclusive result (borderline) | | | | |
| | CVP >>> | 4 | 6,3 | Positive | | | | |